Arvinas reported Phase 1 data for ARV‑102, a PROTAC degrader targeting LRRK2, demonstrating roughly 50% or greater LRRK2 reduction in cerebrospinal fluid at multiple dose levels by day 14 and sustained through day 28. The randomized, placebo‑controlled multiple‑dose cohort also showed dose‑dependent CSF exposure and reductions in endolysosomal and neuroinflammatory biomarkers linked to Parkinson’s disease pathology. Results, presented at AD/PD 2026, indicate blood‑brain barrier penetration and pharmacodynamic activity consistent with target engagement in the CNS. ARV‑102 was well tolerated across tested doses over 28 days. Company statements and trial data suggest further development in PD and related lysosomal dysfunction disorders. Investigators and investors will watch larger cohorts and longer treatment durations for clinical efficacy signals and biomarker correlations to disease modification.